Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02438904 · ClinicalTrials.gov registry record · NA
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
A NA study of Blood And Marrow Transplantation, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT02438904 is a NA study of Blood And Marrow Transplantation that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02438904, a NA study of Blood And Marrow Transplantation, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
Conditions Studied
Interventions
- BIOLOGICAL CD34 Positive Stem Cell Infusion
- DEVICE Miltenyi device
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-05-06 |
| Est. Completion | 2027-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02438904
The ClinicalTrials.gov registry entry for NCT02438904 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Blood And Marrow Transplantation appearing as the primary indexed condition, and to 2 interventions - of which CD34 Positive Stem Cell Infusion is the first listed.
NCT02438904 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02438904 about?
NCT02438904 is a clinical study titled "Compassionate Access of the Miltenyi Device for CD34+ Cell Selection". Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
What is the current status of trial NCT02438904?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2015-05-06. Estimated completion is 2027-05-01.
What conditions does trial NCT02438904 study?
This clinical trial studies the following conditions: Blood And Marrow Transplantation.
What interventions are being tested in trial NCT02438904?
The interventions under investigation include: CD34 Positive Stem Cell Infusion (BIOLOGICAL), Miltenyi device (DEVICE).
Who is sponsoring clinical trial NCT02438904?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02438904 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.